| Birth Day | October 12, 1966 |
| David Grainger age | 57 YEARS OLD |
| Alma mater | Cambridge University |
| Occupation | venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger |
David Grainger's net worth is projected to range between $100,000 and $1 million by 2024. Known as an entrepreneur and wildlife artist, Grainger, in collaboration with his wife Janice Stone, embarked on their entrepreneurial journey by establishing The Guild of Automotive Restorers in 1991. This enterprise gained recognition as a renowned institution specializing in the restoration and preservation of antique automobiles. With their passion for automotive artistry and dedication to craftsmanship, Grainger and Stone have garnered success over the years. As a wildlife artist, Grainger's artistic talents have also contributed to his entrepreneurial endeavors, further adding to his net worth.
Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.
After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University. Following publications in Nature and elsewhere setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system, Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997.
While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001), and Funxional Therapeutics (2005). FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006. Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer until it was sold to Boehringer Ingelheim in 2012.
Grainger joined Index Ventures in 2012, and a Blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”. where he was involved with funding and advising a variety of companies, including XO1, a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier.
He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco, in the firm’s life sciences practice. He also writes for Forbes.com on topics related to the pharmaceutical industry.
